Year: 2009
Type: article
Abstract: Background: Osteosarcoma is the most common pediatric bone tumor. Despite aggressive multimodal therapy survival rates for patients with metastatic or recurrent disease remain poor. New targeted therapies are thus needed to improve outcomes and immunotherapy has the potentials to fulfill this need. We have previously shown that genetically modified T cells expressing a chimeric antigen receptor (CAR) composed of NKG2D and the CD3-ζ chain have potent antitumor activity against several adult malignancies.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2120341761